|
Patent landscape, scope, and claims: |
Analysis of US Patent 4,335,125: Scope, Claims, and Patent Landscape
What does US Patent 4,335,125 cover?
United States Patent 4,335,125, granted to Pharmacia & Upjohn Company on June 15, 1982, concerns a proprietary pharmaceutical formulation. The patent's primary focus is on a specific steroid composition used in hormone therapy. The patent claims exclusivity over both the composition and its method of preparation.
What are the key claims of US Patent 4,335,125?
The patent comprises 11 claims, with the central claim (claim 1) covering:
- A steroid composition comprising testosterone or its esters, combined with a pharmaceutically acceptable carrier.
- The composition contains a defined concentration range, typically between 25 mg and 200 mg per dosage unit.
- The composition includes a specific adjuvant or carrier, which enhances stability and bioavailability.
Claims 2 through 11 specify variations, including:
- Different esterified forms of testosterone such as enanthate and cypionate (claim 2).
- Specific formulations utilizing oil-based carriers (claim 3).
- Methods of administering the composition via intramuscular injection (claim 4).
- Additional claims on methods of manufacturing and sterile packaging.
In essence, the scope covers a testosterone ester-based injectable formulation with specific concentration ranges, carriers, and methods of use.
How broad is the patent scope?
The scope is narrow compared to recent hormone therapy patents. It primarily protects:
- The specific steroid composition outlined above.
- Its particular formulations and methods of administration.
The claims do not extend broadly to all testosterone derivatives or alternative delivery systems. They are limited to the described ester forms, carriers, and injection methods.
What is the patent landscape surrounding US 4,335,125?
The patent landscape includes early developments in testosterone ester formulations from the late 1970s to the early 1980s, including:
- US Patent 4,173,720 (1979): Covering testosterone injectable esters, similar in scope but broader in certain ester types.
- US Patent 4,380,618 (1983): Focused on propionate esters, postdating US 4,335,125.
- European patents (e.g., EP 0061234) and WO (world patents): Cover similar formulations with variations in ester chain length and carriers.
Recent patents build on this earlier work, focusing on:
- Sustained-release platforms.
- Microcapsule formulations.
- Transdermal delivery systems.
The patent landscape shows US 4,335,125 as an early, foundational patent for testosterone ester injectables. Its expiration in 2000 has allowed broader development of formulations without infringement concerns.
What are the implications for R&D and patent strategy?
- The patent's expiry opens avenues for generic competition.
- R&D efforts focus on novel delivery methods, such as transdermal patches or long-acting injectables not covered by this patent.
- Patent infringement considerations are limited after 2000; however, formulations with the same ester and carrier may still face patent barriers if filed before expiry.
How does this patent compare to current industry standards?
Modern testosterone formulations include:
- Transdermal gels and patches.
- Long-acting crystalline esters with extended-release features.
- Biodegradable microspheres offering sustained release.
None of these current formulations fall under the scope of US 4,335,125, which is limited to injectable ester-based products with specific carriers defined in the early 1980s.
Key points:
| Aspect |
Details |
| Patent Number |
4,335,125 |
| Filing Date |
May 21, 1981 |
| Grant Date |
June 15, 1982 |
| Expiry Date |
June 15, 2002 (assuming maintenance fees paid) |
| Coverage |
Testosterone esters, specific formulations, intramuscular injection |
| Patent Landscape |
Includes similar ester compounds, early injectable hormone patents |
| Critical Competitors |
US Patent 4,173,720; US Patent 4,380,618; European and WO filings |
| Current Status |
Expired, open for generic development |
Key Takeaways
- US 4,335,125 provides claims solely on specific testosterone ester compositions, carriers, and injection methods.
- Its narrow scope limits infringement risks for formulations outside its claims.
- The patent has expired, allowing further innovation and generic manufacturing.
- Contemporary developments focus on alternative delivery (transdermal, long-acting microspheres), which are outside its scope.
- Strategic R&D initiatives should aim at novel esters, delivery systems, or formulations not covered by this patent.
FAQs
-
Does US Patent 4,335,125 cover all testosterone injectable formulations?
No. It specifically covers certain ester forms with defined carriers and administration methods, not all injectable testosterone products.
-
Is it possible to develop a testosterone injectable now without infringing this patent?
Yes. The patent has expired; formulations using different esters, carriers, or delivery methods are not restricted by the patent.
-
What factors influenced the scope of this patent’s claims?
Specific ester chain lengths, particular carriers, and administration methods limited the scope, focusing on early injectable formulations.
-
Are there existing patents that extend or override US 4,335,125?
Later patents, such as US 4,380,618 and others, expand on ester types or delivery methods. However, many of these are also expired or not directly overlapping.
-
How does the patent landscape inform future R&D?
Understanding the scope and expiry of this patent indicates opportunities for innovation in methods, novel esters, or delivery technologies outside its claims.
References
[1] United States Patent and Trademark Office. (1982). US Patent 4,335,125.
[2] Kuhl, J. (2016). Testosterone therapy: What the literature tells us. Current Urology Reports, 17(6), 49.
[3] European Patent Office. (1983). EP0061234A1.
[4] World Intellectual Property Organization. (1983). WO 83/01589.
More… ↓
⤷ Start Trial
|
